Delving into the Latest Updates on Icure Pharmaceutical Inc. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Other Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	6
Endocrinology and Metabolic Disease	5
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6
Synthetic peptide	1

Top 5 Target	Count

AChE(Acetylcholinesterase)	3
GLP-1R(Glucagon-like peptide 1 receptor)	1
Opioid receptors	1
D2 receptor x D3 receptor	1
SCNA(Sodium voltage-gated channel alpha subunits)	1

The objective of this study is to evaluate the efficacy and safety of donepezil transdermal patch in patients with mild to moderate Alzheimer's disease.
The primary objective is to demonstrate the non-inferiority of the test drug, IPI-301 (donepezil transdermal patch), to the comparator, Aricept tablet, after 24 weeks of treatment in patients with mild to moderate Alzheimer's disease in terms of improvement in cognitive function as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) and in terms of global assessment as assessed by Clinician's Interview Based Impression of Change plus Caregiver Input (CIBIC-plus).

Start Date12 Oct 2017

Sponsor / Collaborator

Icure Pharmaceutical Inc.

NCT02178124 / CompletedPhase 1

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.

Study of the Safety, tolerability and pharmacokinetics with multiple doses of donepezil patch in healthy male subjects

Start Date01 Jul 2014

Sponsor / Collaborator

Icure Pharmaceutical Inc.

NCT01860625 / CompletedPhase 1

A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects

Study of the Safety, tolerability and pharmacokinetics with single dose of donepezil patch in healthy male subjects.

Start Date01 Apr 2013

Sponsor / Collaborator

Icure Pharmaceutical Inc.

100 Clinical Results associated with Icure Pharmaceutical Inc.

Login to view more data

0 Patents (Medical) associated with Icure Pharmaceutical Inc.

Login to view more data

1

Literatures (Medical) associated with Icure Pharmaceutical Inc.

Drug Design, Development and TherapyQ3 · MEDICINE

<p>Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers</p>

Q3 · MEDICINE

ArticleOA

Author: Yoon, Seok Kyu ; Bae, Kyun-Seop ; Choi, Young Kweon ; Kim, Seong Su ; Lim, Hyeong-Seok ; Hong, Dong Hyun

INTRODUCTIONThis study characterized the pharmacokinetics (PKs) of a donepezil patch formulation currently under development, using mixed effect modeling analysis, and explored optimal patch dosing regimens in comparison with the donepezil oral formulation.METHODSPK data used in this analysis were from 60 healthy Korean male subjects participating in two Phase I studies, where subjects received single or multiple doses of donepezil of 43.75, 87.5, and 175 mg via patches, and 12 of them received a single oral dose of 10 mg of donepezil, followed by a single dose of donepezil via a patch. Donepezil PKs were analyzed by nonlinear mixed effect modeling using NONMEM software.RESULTSA well-stirred model with two-compartment distribution and delayed absorption was chosen as the best model for the oral formulation. The PKs of donepezil after the patch applications were best described by a two-compartment linear model with zero-order absorption (D2) and absorption delay. The relative bioavailability (BA) of donepezil after the patch application compared with oral dosing was described to be affected by the duration of patch application.CONCLUSIONPK simulations based on the chosen PK models suggested that, overall, donepezil exposure in plasma is similar whether with 10 mg of oral donepezil every 24 h or a 175 mg patch every 72 h, and likewise with 5 mg of oral donepezil every 24 h or an 87.5 mg patch every 72 h.

100 Deals associated with Icure Pharmaceutical Inc.

Login to view more data

100 Translational Medicine associated with Icure Pharmaceutical Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

5

2

Phase 3 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Donepezil Hydrochloride ( AChE )	Alzheimer Disease More	Phase 3
Donepezil Pamoate ( AChE )	Alzheimer Disease More	Phase 3
Lidocaine ( SCNA )	Asthma More	Phase 1
Pramipexole Dihydrochloride ( D2 receptor x D3 receptor )	Parkinson Disease More	Phase 1
Fentanyl ( Opioid receptors )	Pain More	Phase 1